Amneal Pharmaceuticals, Inc. $AMRX Shares Acquired by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon increased its Amneal Pharmaceuticals stake by 84.3% in the first quarter to 914,089 shares, while institutional investors collectively own 31.82% of AMRX.
• Amneal reported strong second-quarter 2026 results, with revenue of about $796 million and adjusted EPS of $0.30, exceeding analyst expectations. Management also raised full-year revenue guidance to $3.1–$3.2 billion and expects a debt repricing to reduce interest costs.
• Analyst sentiment remains positive, with seven Buy ratings and one Hold rating producing a consensus “Moderate Buy” rating, though the $17.33 consensus price target is below the stock’s reported $18.32 price.

Bank of New York Mellon Corp boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 84.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 914,089 shares of the company's stock after purchasing an additional 418,241 shares during the period. Bank of New York Mellon Corp owned about 0.29% of Amneal Pharmaceuticals worth $11,362,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of AMRX. Kemnay Advisory Services Inc. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter valued at $26,000. Federated Hermes Inc. boosted its position in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company's stock worth $29,000 after buying an additional 2,168 shares in the last quarter. Spire Wealth Management grew its stake in Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company's stock valued at $32,000 after acquiring an additional 1,023 shares during the last quarter. Transamerica Financial Advisors LLC increased its holdings in Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company's stock valued at $37,000 after acquiring an additional 2,460 shares in the last quarter. Finally, Comerica Bank increased its holdings in Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company's stock valued at $30,000 after acquiring an additional 1,957 shares in the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ AMRX opened at $18.32 on Friday. The company has a 50-day simple moving average of $16.23 and a 200-day simple moving average of $14.26. The company has a debt-to-equity ratio of 77.65, a current ratio of 2.20 and a quick ratio of 1.59. The company has a market cap of $5.84 billion, a PE ratio of 37.39 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a 12 month low of $7.66 and a 12 month high of $19.26.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. On average, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday. Wall Street Zen upgraded Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, July 12th. UBS Group upped their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Zacks Research cut Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, April 6th. Finally, Barclays raised their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an "overweight" rating in a research report on Wednesday, May 20th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Amneal Pharmaceuticals News Roundup

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q2 results exceeded expectations. Amneal reported revenue of approximately $796 million, GAAP net income of $58 million, adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30, above the $0.24 analyst consensus and up from $0.25 a year earlier. Amneal Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $3.1 billion to $3.2 billion, compared with a prior outlook near $3.1 billion, suggesting continued confidence in demand and operating performance. AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
• Positive Sentiment: Debt repricing should reduce interest expense. The company completed a July debt repricing, which is expected to lower borrowing costs and support future earnings and cash flow. Amneal Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: EPS guidance was broadly in line with consensus. Amneal forecast 2026 EPS of $0.96 to $1.06 versus the $0.97 consensus estimate. While the midpoint is slightly above expectations, the range does not represent a major upward revision.
• Negative Sentiment: Investors may be taking profits after the earnings-driven rally. The strong quarterly beat and revenue outlook improvement were likely already reflected in the stock after its recent advance, leaving limited upside when full-year earnings guidance was only modestly better than expectations. Amneal beats expectations in strong Q2 2026

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company's stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 17.30% of the stock is owned by company insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.